Company intelligence / Profile preview
Nuvation Bio
New York, New York, United Statesnuvationbio.com ↗
- Ownership
- Public · NUVB
- Development stage
- NDA
01
Overview
Taletrectinib (3rd generation ROS1 inhibitor) is approved in China for advanced ROS1+ NSCLC and under FDA priority review in the US with PDUFA date of June 23, 2025. Safusidenib (brain-penetrant IDH1 inhibitor) is entering pivotal studies for diffuse IDH1-mutant glioma. NUV-1511 (drug-drug conjugate) is in Phase 1/2 studies. NUV-868 (BD2-selective BET inhibitor) has completed Phase 1 and Phase 1b studies.[4][5]
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesDrug-drug conjugates (DDC)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Daiichi Sankyo (taletrectinib licensing)Sagard Healthcare Partners (financing)
04
Financials
- Market cap
- $1.5B
- Total revenue
- $62.9M
- Enterprise value
- $1.3B
Beyond the preview
Go deeper on Nuvation Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuvation Bio.